Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Hypopharyngeal Squamous Cell Carcinoma
- Metastatic Laryngeal Squamous Cell Carcinoma
- Metastatic Oral Cavity Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Squamous Cell Carcinoma
- Recurrent Neck Squamous Cell Carcinoma of Unknown Primary
- Recurrent Oral Cavity Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Refractory Head and Neck Squamous Cell Carcinoma
- Refractory Hypopharyngeal Squamous Cell Carcinoma
- Refractory Laryngeal Squamous Cell Carcinoma
- Refractory Oral Cavity Squamous Cell Carcinoma
- Refractory Oropharyngeal Squamous Cell Carcinoma
- Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage IV Hypopharyngeal Carcinoma AJCC v8
- Stage IV Laryngeal Cancer AJCC v8
- Stage IV Lip and Oral Cavity Cancer AJCC v8
- Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
- PROCEDURE: Biospecimen Collection
- BIOLOGICAL: Cetuximab
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- BIOLOGICAL: Pembrolizumab
- PROCEDURE: Positron Emission Tomography
Sponsor
National Cancer Institute (NCI)